-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest forecast data of Intranet, the sales scale of proprietary Chinese medicines in 2022E urban physical pharmacies exceeded 110 billion yuan, down 0.
99%
year-on-year.
The annual sales of 70 proprietary Chinese medicines exceed 300 million, of which 33 are exclusive varieties (including exclusive dosage forms), and 2 new 1 billion single products will be born; 23 exclusive proprietary Chinese medicines rose "against the trend", and 8 rose by more than 10%, with enterprises such as Ling and Jichuan shining
.
99%
year-on-year.
The annual sales of 70 proprietary Chinese medicines exceed 300 million, of which 33 are exclusive varieties (including exclusive dosage forms), and 2 new 1 billion single products will be born; 23 exclusive proprietary Chinese medicines rose "against the trend", and 8 rose by more than 10%, with enterprises such as Ling and Jichuan shining
.
2022E Exclusive proprietary Chinese medicine with terminal sales of more than 300 million yuan in physical pharmacies in China
Source: Intranet database
The 33 exclusive proprietary Chinese medicines cover 9 treatment categories, focusing on respiratory diseases (7), musculoskeletal diseases (5) and cardiovascular and cerebrovascular diseases (5), which shows that proprietary Chinese medicines for common and chronic diseases are more popular in
physical pharmacies.
physical pharmacies.
National medical insurance and OTC products account for the mainstream
.
Of the 33 exclusive proprietary Chinese medicines, 21 are included in the 2021 National Medical Insurance Catalogue (9 Class A and 12 Class B), and 24 are OTC products (13 are double-cross products).
.
Of the 33 exclusive proprietary Chinese medicines, 21 are included in the 2021 National Medical Insurance Catalogue (9 Class A and 12 Class B), and 24 are OTC products (13 are double-cross products).
33 exclusive proprietary Chinese medicines are sold together for nearly 20 billion, and 2 new 1 billion single products will be born
In 2022E, the total sales scale of 33 exclusive proprietary Chinese medicines with terminal sales of more than 300 million yuan in China's urban physical pharmacies is close to 20 billion yuan, a year-on-year increase of about 4.
35%, higher than the sales growth rate of the entire proprietary Chinese medicine market (-0.
99%)
.
35%, higher than the sales growth rate of the entire proprietary Chinese medicine market (-0.
99%)
.
5 varieties of more than 1 billion will lead, among which Zhangzhou Pian Tsai Pharmaceutical Co.
, Ltd.
's Pian Tsai (lozenge) and Kangenbei's enteritis Ning tablets will exceed 1 billion
for the first time.
, Ltd.
's Pian Tsai (lozenge) and Kangenbei's enteritis Ning tablets will exceed 1 billion
for the first time.
Originating from the end of the Ming Dynasty, it has a history of nearly 500 years and is a national-level protected variety
of traditional Chinese medicine.
In recent years, the sales of tablets (lozenges) in physical pharmacies in Chinese cities have increased year by year, and will exceed 1 billion yuan for the first time in 2022, a year-on-year increase of about 11.
34%.
In the ranking of proprietary Chinese medicine products for liver diseases, Pian Tsai (lozenge) has ranked first for many consecutive years, and its market share in this treatment subcategory has increased from 31.
9% in 2016 to 43.
7%
in 2022E.
of traditional Chinese medicine.
In recent years, the sales of tablets (lozenges) in physical pharmacies in Chinese cities have increased year by year, and will exceed 1 billion yuan for the first time in 2022, a year-on-year increase of about 11.
34%.
In the ranking of proprietary Chinese medicine products for liver diseases, Pian Tsai (lozenge) has ranked first for many consecutive years, and its market share in this treatment subcategory has increased from 31.
9% in 2016 to 43.
7%
in 2022E.
In recent years, the sales of tablets (lozenges) in China's urban physical pharmacies (10,000 yuan)
Source: Intranet China's urban physical pharmacy terminal competition pattern
It is worth noting that in 2021, Pian Tmall and JD online platforms will operate the flagship store of Pian Tsai Pharmacy on both Tmall and Jingdong online platforms to better meet the retail needs
of the majority of consumer groups for Pian Tsai and series of products.
According to data from Intranet, the sales of tablets and lozenges in China's online pharmacy terminals soared from less than 100 million yuan in 2020 to more than 900 million yuan in 2021, a year-on-year increase of 1282%.
of the majority of consumer groups for Pian Tsai and series of products.
According to data from Intranet, the sales of tablets and lozenges in China's online pharmacy terminals soared from less than 100 million yuan in 2020 to more than 900 million yuan in 2021, a year-on-year increase of 1282%.
Kangenbei's enteritis tablets are OTC class A (double span) and medical insurance class B varieties, which have the effect of clearing heat and dampness and promoting qi, and are suitable for diarrhea caused by moist heat and gastrointestinal tract and indigestion in children
.
In recent years, the sales of enteritis tablets in China's urban physical pharmacy terminals have continued to grow, and are expected to exceed 1 billion yuan in 2022, a year-on-year increase of 3.
56%.
In the ranking of intestinal proprietary Chinese medicine products, enteritis Ning tablets will occupy the top
position with a market share of 62%.
.
In recent years, the sales of enteritis tablets in China's urban physical pharmacy terminals have continued to grow, and are expected to exceed 1 billion yuan in 2022, a year-on-year increase of 3.
56%.
In the ranking of intestinal proprietary Chinese medicine products, enteritis Ning tablets will occupy the top
position with a market share of 62%.
Sales of enteritis tablets in China's urban physical pharmacies in recent years (10,000 yuan)
Source: Intranet China's urban physical pharmacy terminal competition pattern
8 exclusive proprietary Chinese medicines soared by more than 10%, with Ling, Jichuan.
.
.
Eye-catching
.
.
Eye-catching
In terms of growth rate, 23 of the 33 exclusive proprietary Chinese medicines are expected to increase their sales year-on-year, of which 8 will increase by more than 10%; Among the 10 varieties whose sales declined, Hongmao Medicinal Wine fell from more than 2 billion in 2017 to more than 300 million in 2022E, and sales fell
for five consecutive years.
for five consecutive years.
In 2022E, the terminal sales of physical pharmacies in Chinese cities exceeded 300 million yuan and the growth rate exceeded 10%.
Source: Intranet database
Zhejiang Tianhuang Pharmaceutical's iron maple pellets have achieved double-digit
sales growth for four consecutive years.
This variety has the effect of invigorating qi and nourishing yin, nourishing stomach and jin, and is suitable for dry cough, blurred vision, five heart upset, dry stool, fatigue and so on
caused by qi and yin deficiency.
In the 2022E ranking of Chinese proprietary Chinese medicine products for terminal cough expectorant and asthma in China's urban physical pharmacies, Iron Maple Bucket Granules ranked second
with a market share of about 8.
7%.
In addition, the performance of the product in China's online pharmacy terminals is also eye-catching, with sales growth of nearly 180% in 2021 and sales in the first half of 2022 close to the full year of
2021.
sales growth for four consecutive years.
This variety has the effect of invigorating qi and nourishing yin, nourishing stomach and jin, and is suitable for dry cough, blurred vision, five heart upset, dry stool, fatigue and so on
caused by qi and yin deficiency.
In the 2022E ranking of Chinese proprietary Chinese medicine products for terminal cough expectorant and asthma in China's urban physical pharmacies, Iron Maple Bucket Granules ranked second
with a market share of about 8.
7%.
In addition, the performance of the product in China's online pharmacy terminals is also eye-catching, with sales growth of nearly 180% in 2021 and sales in the first half of 2022 close to the full year of
2021.
In recent years, the sales of iron maple bucket granules at the terminal of physical pharmacies in Chinese cities (10,000 yuan)
Source: Intranet China's urban physical pharmacy terminal competition pattern
In terms of enterprises (in terms of groups), six enterprises have two or more exclusive proprietary Chinese medicines of more than 300 million, namely Yunnan Baiyao, Buchang Pharmaceutical, China Resources Pharmaceutical, Jichuan Pharmaceutical, Sanjin Pharmaceutical and Yiling Pharmaceutical
.
.
More than 300 million exclusive proprietary Chinese medicines up to 2 or more enterprises
The total sales scale of Yiling Pharmaceutical's Lianhua Qingxi series products (capsules, granules, tablets) and Yunnan Baiyao's Yunnan Baiyao series products (aerosols, pastes, powders, capsules, and solutions) reached RMB1.
52 billion and RMB1.
67 billion
, respectively, in 2022E.
52 billion and RMB1.
67 billion
, respectively, in 2022E.
Collective procurement and medical insurance negotiations have taken turns, and retail pharmacies may become a new battlefield
Driven by a series of policies, the pace of inclusion of proprietary Chinese medicines in the national medical insurance catalogue and centralized procurement has continued to accelerate
in recent years.
in recent years.
A few days ago, the National Medical Insurance Administration issued an announcement that the negotiation of national medical insurance in 2022 is like an arrow
.
From the list published so far, a total of 343 drugs have passed the formal examination, of which 50 are proprietary Chinese medicines (15 outside the catalogue and 35 in the catalogue), except for Yixin ketone drop pills, the rest are exclusive varieties (including exclusive dosage forms).
.
From the list published so far, a total of 343 drugs have passed the formal examination, of which 50 are proprietary Chinese medicines (15 outside the catalogue and 35 in the catalogue), except for Yixin ketone drop pills, the rest are exclusive varieties (including exclusive dosage forms).
According to the application conditions passed, among the 15 non-catalogue proprietary Chinese medicines, except for Shixin lozenge, Tangcao tablets and Yixin ketone drop pills, the remaining 12 varieties are all new generic drugs approved for marketing by the national drug regulatory department between January 1, 2017 and June 30, 2022; Among the 35 proprietary Chinese medicines in the catalogue, 4 passed the review with condition 2, that is, negotiated drugs and other drugs
in the catalogue that have undergone significant changes in indications or functional indications approved by the national drug regulatory department between January 1, 2017 and June 30, 2022.
(Including the application for drug renewal in 2022 to adjust the scope of medical insurance payment).
in the catalogue that have undergone significant changes in indications or functional indications approved by the national drug regulatory department between January 1, 2017 and June 30, 2022.
(Including the application for drug renewal in 2022 to adjust the scope of medical insurance payment).
Through the dynamic adjustment of the medical insurance catalogue, more innovative proprietary Chinese medicines will enter the medical insurance catalogue
.
With the support of the "dual channel" policy, these innovative Chinese medicines included in medical insurance are also expected to be scaled up
in retail pharmacies.
.
With the support of the "dual channel" policy, these innovative Chinese medicines included in medical insurance are also expected to be scaled up
in retail pharmacies.
In terms of centralized procurement of proprietary Chinese medicines, the collective procurement of proprietary Chinese medicines in 19 provinces in Hubei and the centralized procurement of proprietary Chinese medicines in 6 provinces in Guangdong have been settled
.
On September 9, the National Joint Procurement Office of Proprietary Chinese Medicines was officially established, and the "Procurement Announcement of the National Alliance of Proprietary Chinese Medicines" was issued, and 30 provinces and municipalities participated in the collective procurement of the alliance of proprietary Chinese medicines, including a total of 42 products
in 16 categories.
.
On September 9, the National Joint Procurement Office of Proprietary Chinese Medicines was officially established, and the "Procurement Announcement of the National Alliance of Proprietary Chinese Medicines" was issued, and 30 provinces and municipalities participated in the collective procurement of the alliance of proprietary Chinese medicines, including a total of 42 products
in 16 categories.
Some industry views believe that due to the large number of participating provinces, the centralized procurement of proprietary Chinese medicines led by Hubei can basically be regarded as the national centralized procurement of proprietary Chinese medicines, which is an important step
in the normalization of centralized procurement of proprietary Chinese medicines.
in the normalization of centralized procurement of proprietary Chinese medicines.
With the continuous advancement of centralized procurement of proprietary Chinese medicines, proprietary Chinese medicines will face more uncertainty in public medical institutions, and retail pharmacies are expected to become a new battlefield
.
.
Source: Intranet database and other notes: Intranet "Terminal Competition Pattern of China's Urban Physical Pharmacies", the statistical scope is: urban physical pharmacies at the prefecture level and above nationwide, excluding county and rural pharmacies; Intranet's "Competition Pattern of China's Online Pharmacy Terminals", the statistical scope is: all drug data of online pharmacies nationwide, including Tmall, Jingdong and other third-party platforms and all online pharmacies on private domain platforms; The above sales are calculated
based on the average retail price of the product at the terminal.
based on the average retail price of the product at the terminal.
